Hemostasis Products: Global Strategic Business Report

Global Hemostasis Products Market to Reach $17.9 Billion by 2030

The global market for Hemostasis Products estimated at US$13.3 Billion in the year 2022, is projected to reach a revised size of US$17.9 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2022-2030. Infusible Hemostasis, one of the segments analyzed in the report, is projected to record a 3.4% CAGR and reach US$8.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Topical Hemostasis segment is readjusted to a revised 3.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $3.6 Billion, While China is Forecast to Grow at 6.2% CAGR

The Hemostasis Products market in the U.S. is estimated at US$3.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 3.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.4 Billion by the year 2030.

Select Competitors (Total 46 Featured) -

• Abbott Laboratories, Inc.
• BARD, A Becton, Dickinson Company
• Baxter International, Inc.
• CSL Behring
• Grifols SA
• Integra Life Sciences Corporation
• Johnson & Johnson
• Medtronic PLC
• Pfizer, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year